Tarsus Pharmaceuticals (TARS) Competitors $43.19 -1.69 (-3.77%) Closing price 04:00 PM EasternExtended Trading$42.54 -0.66 (-1.52%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. BBIO, BPMC, ELAN, LEGN, TGTX, TLX, VRNA, LNTH, AXSM, and GRFSShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. BridgeBio Pharma Blueprint Medicines Elanco Animal Health Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Verona Pharma Lantheus Axsome Therapeutics Grifols BridgeBio Pharma (NASDAQ:BBIO) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking. Does the MarketBeat Community favor BBIO or TARS? BridgeBio Pharma received 126 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 72.47% of users gave BridgeBio Pharma an outperform vote while only 67.95% of users gave Tarsus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBridgeBio PharmaOutperform Votes17972.47% Underperform Votes6827.53% Tarsus PharmaceuticalsOutperform Votes5367.95% Underperform Votes2532.05% Is BBIO or TARS more profitable? Tarsus Pharmaceuticals has a net margin of -103.64% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-241.44% N/A -75.69% Tarsus Pharmaceuticals -103.64%-55.86%-39.28% Does the media refer more to BBIO or TARS? In the previous week, BridgeBio Pharma had 7 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 16 mentions for BridgeBio Pharma and 9 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.53 beat BridgeBio Pharma's score of 0.80 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, BBIO or TARS? BridgeBio Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Do insiders & institutionals believe in BBIO or TARS? 99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better valuation & earnings, BBIO or TARS? Tarsus Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$127.42M48.94-$535.76M-$3.53-9.30Tarsus Pharmaceuticals$233.67M7.77-$135.89M-$2.73-15.82 Do analysts prefer BBIO or TARS? BridgeBio Pharma currently has a consensus price target of $57.09, suggesting a potential upside of 73.85%. Tarsus Pharmaceuticals has a consensus price target of $66.33, suggesting a potential upside of 53.58%. Given BridgeBio Pharma's higher possible upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryBridgeBio Pharma beats Tarsus Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81B$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-11.3430.5026.8419.71Price / Sales7.77400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book7.263.286.794.50Net Income-$135.89M-$72.17M$3.23B$248.18M7 Day Performance0.68%4.28%4.07%1.14%1 Month Performance-10.97%7.62%12.52%15.18%1 Year Performance14.17%-28.15%16.83%6.55% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals3.3008 of 5 stars$43.19-3.8%$66.33+53.6%+15.9%$1.81B$233.67M-11.3450Positive NewsBBIOBridgeBio Pharma4.6002 of 5 stars$35.68+4.4%$57.09+60.0%+14.2%$6.77B$127.42M-12.52400Positive NewsInsider TradeBPMCBlueprint Medicines2.6687 of 5 stars$100.31+3.2%$126.56+26.2%-1.2%$6.48B$562.12M-92.88640Positive NewsELANElanco Animal Health3.5226 of 5 stars$12.82+7.2%$15.00+17.0%-23.1%$6.36B$4.43B32.049,800Analyst ForecastGap UpLEGNLegend Biotech3.5386 of 5 stars$32.38+1.9%$78.82+143.4%-33.8%$5.95B$627.24M-34.081,070News CoverageAnalyst RevisionGap UpTGTXTG Therapeutics3.8254 of 5 stars$34.99+4.0%$40.80+16.6%+115.2%$5.56B$386.39M-349.87290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.25-5.4%$22.00+35.4%N/A$5.49B$783.21M0.00N/AGap DownVRNAVerona Pharma2.6775 of 5 stars$67.53+6.6%$81.50+20.7%+484.7%$5.48B$118.54M-35.1730Positive NewsLNTHLantheus4.458 of 5 stars$79.52-2.7%$132.67+66.8%-7.3%$5.45B$1.54B13.23700Positive NewsHigh Trading VolumeAXSMAxsome Therapeutics4.7267 of 5 stars$110.16+2.2%$172.14+56.3%+39.7%$5.42B$432.16M-18.39380Positive NewsInsider TradeGRFSGrifols3.2195 of 5 stars$7.73+8.9%N/A+4.7%$5.31B$7.21B6.6126,300Positive News Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Verona Pharma Alternatives Lantheus Alternatives Axsome Therapeutics Alternatives Grifols Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARS Stock Free TARS Stock Alerts